A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
Melanoma
DRUG: YM155
Tumor response rate, 6 cycles
Duration of response, 6 cycles
A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155